Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, US-based experts reached a consensus on treating adults with severe alopecia areata, recommending oral Janus kinase inhibitors as the primary long-term therapy, while also suggesting supplemental treatments like minoxidil and corticosteroids, with a call for more research on specific patient subpopulations.

This review discusses various treatment options for chronic central serous chorioretinopathy, evaluating studies conducted since 2000, but reports no new clinical results.

This study found that the expression of androgen receptors is higher in the scalp area affected by androgenetic alopecia, and its expression varies based on different traditional Chinese medicine syndromes.

This study developed a simplified multidimensional assessment scale for alopecia areata severity and systemic treatment initiation among Chinese patients, achieving expert consensus on relevant clinical indicators and conditions.

In this report, two adult patients with Tatton-Brown-Rahman syndrome exhibited new cardiac features, such as atrial fibrillation and ventricular and atrial dilatation, highlighting the importance of cardiovascular follow-up in adults with this condition.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

This article discusses arsenic trioxide as a treatment for refractory or relapsed acute promyelocytic leukemia, noting its effectiveness and manageable side effects.

This opinion piece discusses strategies for managing cancer-related alopecia, emphasizing personalized approaches including scalp cooling and topical minoxidil, but it reports no new clinical results.

This review discusses the roles of androgens and androgen receptors in skin-related disorders and suggests that targeting androgen receptors may be a more effective treatment strategy.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

In this ongoing phase 3 study, ritlecitinib demonstrated sustained efficacy up to 24 months in patients aged 12 or older with alopecia areata, showing increased response rates with or without an initial loading dose and supporting its long-term use.

This review discusses the genetics and variable phenotypic expression of nonclassic congenital adrenal hyperplasia, and reports no new clinical results; the authors call for further research on long-term health impacts and treatment strategies.

This study is set to explore acupuncture's effects on seborrheic alopecia through a randomized controlled trial, aiming to assess its clinical effectiveness and safety.

In this study, researchers found that the management of alopecia areata in Poland is inadequate, despite following international guidelines, due to limited access to advanced treatments and insufficient use of severity assessments and psychosocial support.

This quiz presents educational questions about alopecia areata, including its diagnosis and underlying mechanisms, but reports no new clinical outcomes.

This study found that the count of CAG trinucleotide repeats in the androgen receptor gene may be associated with acne in female patients without hyperandrogenism.

CCCA may be a fibroproliferative disorder, and anti-fibrotic therapies could help.

This article outlines opportunities for academic growth provided by the Indian Association of Dermatologists, Venereologists, and Leprologists, reporting no new research findings.

This review explores the pathogenesis, diagnosis, and treatment options for chronic autoimmune urticaria, highlighting the role of the oncostatin M receptor gene and reporting no new clinical results.

This case collection reports that 15% azelaic acid gel can be effectively used as a monotherapy to treat mild-to-moderate adult female acne.

Results are not reported in this source. The abstract does not provide a summary or findings from the Australasian Journal of Dermatology regarding contact dermatitis.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.

This article reviews the identification and assessment of cutaneous drug reactions, emphasizing the importance of early recognition and the need for accurate diagnosis to prevent serious complications; it reports no new clinical results.

This study observed a significant association between antigliadin antibodies (IgA and IgG) and alopecia areata severity, suggesting that serological tests could help diagnose subclinical celiac disease in these patients, with IgA and IgG showing 100% sensitivity and specificity at specific cutoff points.

This study found that altered amino acid metabolism, specifically involving glutamic and aspartic acids, promotes neurovascular reactivity in rosacea, suggesting a potential metabolic target for treatment.

New acne treatments include combination creams, advanced retinoids, and light therapies, focusing on safety and patient adherence.

This review discusses cultural hair care practices for African American scalp health and recommends combining clinical evaluation with cultural knowledge, but reports no new research findings.

In this study, the researchers reported that baricitinib improved hair loss in a real-world setting for Japanese adults with alopecia areata, with a 64.7% success rate at 60 weeks, though prolonged episodes reduced efficacy. Common side effects were acne and mildly decreased renal function.

In this study, distinct molecular mechanisms of action were identified for three drugs used in alopecia areata clinical trials, providing insights for precision medicine and treatment selection.

Capsaicin cream quickly relieved itching in two patients with brachioradial pruritus.